The adverse impact of a gain in chromosome 1q on the prognosis of multiple myeloma treated with bortezomib-based regimens: A retrospective single-center study in China

The adverse impact of a gain in chromosome 1q on the prognosis of multiple myeloma treated with bortezomib-based regimens: A retrospective single-center study in China

BackgroundMultiple myeloma is genetically heterogeneous, and chromosome abnormalities play a pivotal role in prognosis. A gain in chromosome 1q (+1q) is among the most common cytogenetic abnormalities; however, its relationship with overall survival (OS) and progression-free survival (PFS) in patien...

Full description

Bibliographic Details
Main Authors: Qingxiao Chen, Xiaoyan Han, Gaofeng Zheng, Yang Yang, Yi Li, Enfan Zhang, Li Yang, Mengmeng Dong, Donghua He, Jingsong He, Zhen Cai
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-12-01
Series:Frontiers in Oncology
Subjects:
1q gain
myeloma
bortezomib
chinese population
single center
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2022.1084683/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2022.1084683/full

Similar Items